The legal victory represents a significant reduction in the risk profile of the company. The company's fending off of this major threat is likely to lift sentiment for the entire large-cap pharmaceutical group through the remainder of 2005.

The squeeze is coming, ... With this number of cases and these types of awards, the stability of the company is at risk.

They got slammed. The credibility of this company has been damaged and will continue to be so for some time until they can deliver.

This is an important victory not only for Pfizer but for all innovators pursuing high-risk medical discoveries.

If this particular company and this particular country does not join the modern economy, it stands every risk of being left behind. But clearly, if it did it in a thoughtless way and tried to meet this demand of the market immediately, it would have created chaos.

When all is said and done, we expect the company will likely be able to exceed its conservative forecast.